AMT-130 submission: clinical evidence supporting the September 2 application

September 2, 2026: application submitted

uniQure announced submission of a BLA seeking accelerated approval of ifezuntirgene inilparvovec (AMT-130) for Huntington’s disease, alongside a UK MAA. This report records that completed submission milestone. It does not record FDA filing acceptance, a granted priority review, an assigned PDUFA date or approval. The supporting evidence below is the previously disclosed three-year dataset; no four-year efficacy values are substituted. [4]

The original prospective four-year dossier remains a separate record, linked in the references. Its trial evidence is retained here because it explains the basis of this application. A submission demonstrates delivery of a dossier, not that regulators have endorsed the external comparator, the magnitude of benefit or the proposed indication. Those questions remain open until the relevant agency assessment is available.

Biology / Target

AMT-130 is a one-time gene-therapy approach intended to reduce huntingtin expression. Its clinical claim concerns slowing decline in Huntington’s disease, not reversing every established deficit or curing the genetic disorder. [1] [3]

In a progressive disease, stabilization may be useful even without an absolute score increase. But the counterfactual—what the same patient would have experienced untreated—must be credible. Biological rationale alone cannot establish that counterfactual.

Concordant functional, motor and biomarker directions can strengthen an interpretation, but correlated endpoints are not independent replications. A composite scale and its components may share information, so several favorable p-values should not be counted as several unrelated experiments.

Molecule / Delivery and PK–PD

The program uses direct neurosurgical delivery into the striatum. The US study included a sham-controlled core period, but the widely cited 36-month comparison uses external natural-history controls. Those are different comparison designs. [1] [3]

For a locally delivered gene therapy, dose, distribution and viable target tissue can matter as much as administered vector quantity. CSF biomarker behavior is supportive but not a direct spatial map of target suppression throughout the relevant brain structures.

Higher-dose and lower-dose cohorts may differ in timing, procedures and eligibility. A stronger high-dose result is compatible with a dose effect, but it is not a clean randomized dose-response estimate unless these differences and uncertainty are addressed.

Clinical evidence: actual denominators and comparator

The 2025 analysis included 29 treated patients: 17 high-dose and 12 low-dose. Twelve in each dose group had reached Month 36. The matched external-control datasets comprised 940 and 626 respectively; these are not randomized controls. [1]

A large external dataset cannot compensate for a small treated cohort’s susceptibility to selection and individual trajectories. Precision conditional on a matching model is different from protection against unmeasured confounding.

Four-year follow-up / Statistical interpretation

The July 2026 update guided September four-year data for 24 patients, 12 per dose. It also described FDA discussions on a confirmatory study and a potential accelerated-approval submission. These are company-reported regulatory discussions, not an approval decision. [2]

The four-year question is whether the separation persists under the same analysis rules. Compare the same participants over time; adding a different subset can alter an average even when no individual trajectory changes. Report losses, deaths, missed visits and analysis exclusions explicitly.

Propensity matching balances measured variables, not unknown prognostic factors. Check age, disease burden, baseline function, site assessments, calendar era and eligibility overlap. Sensitivity to alternative external datasets is helpful, but cannot reproduce the protection of random assignment.

An apparent percentage slowing can become unstable when the comparator change is small. Absolute changes, confidence intervals and individual trajectories should therefore lead the interpretation. No four-year efficacy estimate is invented before verified disclosure.

Safety / Procedure and delayed effects

The 2025 release reported no new drug-related serious events since December 2022. “No new” over a specified interval does not mean none occurred in the entire program. [1]

Separate surgical complications, immune suppression, vector-related inflammation and background disease events. A persistent intervention needs long-term surveillance even after an initially manageable safety profile. Missing total SAE or death tables should remain missing, not be converted into zero.

Capital structure / Management

The operational dependency is a credible confirmatory study alongside long-term follow-up. A proposed regulatory route can require additional enrollment and manufacturing work; its feasibility should be assessed separately from an encouraging early efficacy pattern. [2]

Capitalization is not independently reconciled here. Management evidence should focus on the consistency of regulatory communications, whether complete data are published and whether the confirmatory design can genuinely resolve the external-control limitations.

Application evidence / Population and analysis boundaries

The clinical programs are identified as NCT04120493 and NCT05243017 in the 2026 submission release. The original US randomized sham comparison and the later matched Enroll-HD analysis answer different questions. A sham participant who subsequently received therapy cannot continue to serve as an untreated long-term comparator. The historical enrollment counts below are not interchangeable with the number contributing an outcome at Month 36. [1] [4]

The public announcements do not supply the complete protocol, estimand specification, missing-visit strategy, individual trajectories, or all confidence intervals. These gaps prevent independent reproduction of the confirmatory analysis. A lower decline in a selected treated cohort is compatible with benefit, but residual differences in disease course, assessment and selection may contribute. Regulatory acceptance of a study plan would not eliminate those methodological limitations.

Safety evidence available at submission

The submission announcement does not replace the earlier safety account with a complete integrated safety dataset. The table therefore distinguishes unreported quantities from observed zero. For an irreversible intracranial intervention, procedure-related and delayed vector-related effects require separate attribution and follow-up. Historical reassurance over one interval cannot establish the incidence of rare or late complications. [1] [4]

Execution update: financing and confirmatory work

The July 29 financial update reported $810.3 million of cash, cash equivalents and current investments at June 30, 2026, and management projected funding into 2030. A June equity offering raised $259 million gross through 5,686,813 shares at $45.50. Gross proceeds are not net cash available after fees, and this snapshot is not a reconciled fully diluted share count. [2]

Analysis: the financing supports the ability to continue follow-up, manufacture treatment and organize a confirmatory study, but it is not clinical validation. The next evidence milestones are agency filing decisions, a documented confirmatory design and a separately disclosed four-year analysis. Their dates and outcomes should be recorded only when supported by new primary disclosures; no review deadline is calculated from the submission date here.

Sources / References

1. uniQure · Phase I/II topline results · September 24, 2025
2. uniQure · Q2 2026 update · SEC Exhibit 99.1, July 29, 2026
3. uniQure · AMT-130 clinical trial design
4. uniQure · BLA and UK MAA submission announcement · September 2, 2026; verified September 16
5. Separate four-year follow-up catalyst and original evidence